BMRN
Biomarin Pharmaceutical
$60.27
+$0.94 (+1.58%)Jul 27, 2026
Key metrics
The numbers that frame BMRN today
- Market cap
- $11.65B
- P/E (TTM)
- 43.3
- EV / FCF
- 13.0
- Gross margin
- 76.5%
- EV / Sales
- 3.1
- ROIC
- 7.1%
- Div yield
- 0%
- Debt / equity
- 0.2
- 52wk Low
- $49.26
- 52wk High
- $66.28
Growth
Revenue and earnings trend for BMRN
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about BMRN
Is Biomarin Pharmaceutical a good buy?
Hold. Biomarin Pharmaceutical has mixed quality and mixed momentum. The setup is mixed. Growth looks mixed. The support signal is useful, but not decisive. We think Biomarin Pharmaceutical is selling at a low price.
What is the market capitalization of BMRN?
Biomarin Pharmaceutical's market capitalization is $11.65B.
What is the P/E ratio for BMRN stock?
Biomarin Pharmaceutical's current P/E ratio is 43.3.
What is the 52-week high for BMRN stock?
The 52-week high for Biomarin Pharmaceutical is $66.28. The current close of $60.27 is 9.1% below that high.
What is the 52-week low for BMRN stock?
The 52-week low for Biomarin Pharmaceutical is $49.26. The current close of $60.27 is 22.4% above that low.
Does BMRN stock pay dividends?
Biomarin Pharmaceutical does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for BMRN?
Biomarin Pharmaceutical's Debt / Equity ratio is 0.23.